Teva Leapfrogs Mylan And Sandoz On Linaclotide
Settlement Permits Generic Linzess Launch In 2029
• By Aidan Fry
Teva has reached a patent-litigation settlement that will allow it to leapfrog its rivals into the US linaclotide market • Source: Shutterstock 
